Projected Health and Economic Impact of Rotavirus Vaccination in GAVI-Eligible Countries: 2011–2030
This article, published in Vaccine, projects the cost-effectiveness and health impact of rotavirus vaccines in countries eligible for support from the GAVI Alliance. The authors used a decision-analytic model to project the health outcomes and direct costs of a birth cohort in the target population, with and without a rotavirus vaccine. They found that rotavirus vaccination in GAVI-eligible countries would prevent 2.46 million childhood deaths and 83 million disability-adjusted life years (DALYs) from 2011 to 2030, with annual reductions of 180,000 childhood deaths at peak vaccine uptake. The cost per DALY averted is US$42 for all GAVI countries combined, over the entire period. The authors conclude that rotavirus vaccination would be considered very cost-effective for all GAVI countries. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author(s): Atherly DE, Lewis KDC, Tate J, Parashar UD, Rheingans RD
Visit web page (English)
(Located at www.sciencedirect.com)
Citation: Atherly DE, Lewis KDC, Tate J, Parashar UD, Rheingans RD. Projected Health and Economic Impact of Rotavirus Vaccination in GAVI-Eligible Countries: 2011–2030. Vaccine. 2012;30(Supplement 1):A7-A14.